ReviewTranslational cancer research2026
Modern radiotherapy in inoperable locally advanced non-small cell lung cancer: a review of techniques, dose fractionation, and immuno-synergistic strategies.
Review in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For patients with inoperable locally advanced non-small cell lung cancer (LA-NSCLC), concurrent chemoradiotherapy followed by durvalumab consolidation is the current standard of care. However, local recurrence remains a predominant therapeutic obstacle. This review therefore aims to synthesize recent advancements in radiotherapy techniques, dose optimization, and immunotherapy integration to provide references for clinical practice and future research. This review synthesizes current literature to evaluate advancements in radiotherapy techniques, dose fractionation strategies, and their integration with immunotherapy. Intensity-modulated radiotherapy (IMRT) has become the standard technique, with long-term follow-up data confirming its survival benefits and safety. Advanced techniques including stereotactic body radiotherapy (SBRT) and particle therapy show potential for dose escalation but are limited by toxicity and a lack of high-level evidence. High-dose-rate brachytherapy (HDR-BT) demonstrates favorable local control with low toxicity and cost-effectiveness, though broader application awaits further validation. Regarding dose strategies, conventional dose escalation failed to improve survival, while hypofractionated radiotherapy shows promise in balancing efficacy and toxicity. The synergy with immunotherapy represents a new paradigm, with clinical trials actively exploring optimal combinations and leveraging radiotherapy's immunomodulatory potential. This review summarizes the current landscape and advancements in radiotherapy for LA-NSCLC. Future treatment strategies should develop personalized approaches based on multidisciplinary collaboration, utilizing precision radiotherapy to safely enhance treatment intensity, applying novel biomarkers to guide clinical decision-making, and optimizing combination strategies with immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.